Cytalon 100 mg, 500 mg and 1000 mg Cytarabine Injection Vials

At a Glance

Generic Name: Cytarabine

Brand Name: Cytalon

Strength & Pack Size: 100 mg, 500 mg and 1000 mg single-use cytarabine vials

Dosage Form & Route: Lyophilised powder for IV, subcutaneous or intrathecal injection after reconstitution

Therapeutic Class: Antimetabolite chemotherapy (pyrimidine analogue)

Primary Indications: Acute leukaemias and related blood cancers, as per specialist protocols

Usual Use in Therapy: Induction, consolidation or intensification cycles in combination regimens

Prescription Status: Prescription-only cytotoxic medicine for hospital or specialist centre use

Storage: Store in the original carton below 25 °C, protected from light, and handle as cytotoxic

Product Description

Cytalon is a cytarabine-based injectable chemotherapy used in the treatment of acute leukaemias and related blood cancers under the supervision of experienced haematology teams. Each Cytalon vial contains cytarabine as a lyophilised powder that must be reconstituted with an appropriate diluent before use. Depending on the regimen, the reconstituted solution may be given intravenously, subcutaneously or, in specific protocols, by other specialist routes such as intrathecal administration. The availability of Cytalon 100 mg, 500 mg and 1000 mg vials allows clinicians to match the total cytarabine dose to body-surface-area–based calculations and specific cycle designs with precision.

Cytarabine has long been a cornerstone of acute myeloid leukaemia treatment and also features in regimens for other forms of leukaemia and certain haematologic conditions. Cytalon cytarabine vials can be incorporated into induction schedules aimed at rapidly reducing leukaemic blast counts and into consolidation or intensification phases designed to deepen and prolong remission. The exact role of Cytalon in an individual treatment plan depends on disease subtype, prior therapy, co-morbidities and local or international protocols followed by the treating centre. Cytalon cytarabine is not used as a self-administered medicine at home; all preparation and administration are carried out by trained healthcare professionals.

Generic Meds Mart supplies Cytalon 100 mg, 500 mg and 1000 mg cytarabine vials in original manufacturer cartons obtained from licensed oncology distributors. Each pack displays the brand name, strength, generic name, batch number, expiry date and storage conditions so hospital pharmacy teams can verify every vial before it is added to chemotherapy preparation workflows. Parcels are shipped in neutral outer packaging that does not mention leukaemia, cytarabine or chemotherapy, supporting patient privacy while still providing the traceability needed for safe cytotoxic handling. Our role is to support medicine access and logistics; all therapeutic decisions remain with your haematologists and oncologists.

Key Uses

Cytalon cytarabine vials are used in the management of various acute leukaemias and related blood cancers, most notably acute myeloid leukaemia. Cytarabine may also be part of regimens for acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crisis and certain meningeal or central nervous system involvements where intrathecal schedules are prescribed. Cytarabine is almost always used in combination with other chemotherapy agents and supportive measures rather than as a single agent.

The specific indication and schedule for Cytalon cytarabine depend on the precise leukaemia subtype, cytogenetic risk profile, age, organ function, infection status and previous treatments a patient has received. Some regimens use standard-dose cytarabine, while others employ high-dose cytarabine blocks as part of consolidation. Your haematology team will determine whether Cytalon cytarabine is suitable in your situation and, if so, at which stage of the treatment pathway it should be used and with which combination partners.

How Cytarabine Works in Chemotherapy

Cytarabine, the active ingredient in Cytalon, is an antimetabolite and pyrimidine analogue that interferes with DNA synthesis in rapidly dividing cells. Once administered, cytarabine is taken up into cells and converted into an active triphosphate form that competes with natural nucleotides during DNA replication. By being incorporated into growing DNA strands, cytarabine disrupts chain elongation and inhibits key enzymes, particularly DNA polymerase, that are essential for accurate DNA synthesis.

Leukaemic blasts and other rapidly dividing malignant cells rely heavily on continuous DNA replication, which makes them particularly vulnerable to cytarabine’s mechanism of action. As DNA synthesis becomes impaired, these abnormal cells accumulate damage and undergo cell death. Normal cells that divide quickly, such as bone marrow progenitors and gastrointestinal lining cells, can also be affected, which explains many of the side effects associated with cytarabine. The balance between anti-leukaemic efficacy and toxicity is carefully managed by experienced clinicians through dosing schedules, supportive care and close monitoring.

Dosage & Administration

Cytalon cytarabine dosage is determined entirely by the treating haematology team and often expressed in milligrams per square metre of body surface area. Regimens may involve continuous infusions over several days, intermittent infusions, subcutaneous injections or specialised intrathecal doses, depending on the protocol and disease setting. Cytalon 100 mg, 500 mg and 1000 mg vials provide flexibility for pharmacists and chemotherapy nurses to reconstitute the exact total cytarabine dose needed for each cycle or treatment block.

Cytalon vials must be reconstituted with the recommended diluent by trained staff using aseptic technique in a controlled preparation area, often a pharmacy clean room or chemotherapy mixing space. The reconstituted solution is then administered via a central or peripheral line, subcutaneous injection or other defined route, with patients monitored during and after treatment for side effects and infusion-related issues. Schedules typically include rest periods between cycles to allow bone marrow recovery and management of toxicities. Patients should never attempt to handle or inject Cytalon cytarabine themselves.

Precautions

Before starting Cytalon cytarabine, your medical team will review your blood counts, liver and kidney function, cardiac status, neurological history and any current infections. Cytarabine can cause profound bone marrow suppression, so a baseline full blood count and frequent monitoring during treatment are essential. Existing infections need to be treated and controlled, as cytarabine further suppresses the immune system and can increase the risk of serious or opportunistic infections.

Cytarabine may also affect liver and kidney function, so dose adjustments or special precautions might be necessary for patients with impaired organ function. In high-dose or intrathecal regimens, cytarabine has been associated with neurological side effects, so any previous neurological conditions will be taken into account when designing a treatment plan. Because cytarabine can be harmful to a developing baby, effective contraception is usually required during therapy and for a period afterwards, and cytarabine is generally avoided in pregnancy and breastfeeding unless there is a compelling reason and this is clearly documented by the treating team.

Cytarabine Side Effects

Common side effects

Common cytarabine side effects include bone marrow suppression leading to low white blood cell counts, low red cells and low platelets, which can manifest as increased susceptibility to infections, fatigue, pallor, easy bruising or bleeding. Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal discomfort and mouth sores are also frequent, particularly at higher doses. Many patients experience hair thinning or hair loss, loss of appetite, mild fever, general weakness and injection-site irritation or phlebitis at the infusion site. These effects are often managed with anti-nausea medicines, mouth care protocols, growth factors, transfusions and supportive measures guided by the haematology team.

Serious side effects

Serious cytarabine adverse effects require urgent medical attention and may lead to dose adjustment or discontinuation. These include severe infections or sepsis in the setting of neutropenia, significant bleeding due to marked thrombocytopenia, severe mucositis, pronounced liver or kidney dysfunction, and rare but important neurological events such as cerebellar toxicity with unsteady gait, slurred speech or coordination difficulties. High-dose cytarabine or intrathecal cytarabine regimens need especially careful neurological monitoring. Any high fever, chills, confusion, unusual bruising, black or bloody stools, sudden difficulty walking, severe headache or new visual changes during Cytalon therapy should be reported immediately to the treating team or emergency services.

Storage

Unopened Cytalon 100 mg, 500 mg and 1000 mg vials should be stored below 25 degrees Celsius in their original cartons, protected from light and moisture, and handled in accordance with local cytotoxic medicine guidelines. Reconstituted cytarabine solutions have limited stability and must be used or discarded according to the product information and institutional policies, usually under the supervision of the hospital pharmacy or chemotherapy unit. Patients themselves are not expected to store, transport or dispose of reconstituted Cytalon vials; this is managed entirely by clinical staff using approved cytotoxic waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart helps hospitals, clinics and patients access Cytalon cytarabine vials in regions where supply, cost or local distribution may otherwise limit choice. We work only with licensed oncology manufacturers and authorised distributors who follow Good Manufacturing Practice standards and maintain rigorous batch and expiry tracking. By supplying Cytalon 100 mg, 500 mg and 1000 mg vials in sealed, original cartons, we support hospital pharmacies in verifying product identity and strength before incorporation into chemotherapy protocols.

All Cytalon orders through Generic Meds Mart are processed in USD via secure online checkout, and shipments are packed in neutral outer cartons that do not mention leukaemia, cytarabine or chemotherapy. Where available, trackable delivery options allow haematology services to plan upcoming induction or consolidation cycles around confirmed delivery dates, helping to reduce the risk of treatment delays caused by supply issues. Our role is to support timely, discreet and verifiable access to the cytarabine strengths prescribed by your specialists; all decisions about when and how to use Cytalon remain strictly with your medical team.

Order Now

Before ordering Cytalon from Generic Meds Mart, you should already have a confirmed diagnosis of acute leukaemia or a related blood cancer and a clear written treatment plan from your haematologist that specifies cytarabine, the intended dose, the number of cycles and the route of administration. Your treating centre will determine whether Cytalon is a suitable cytarabine brand for your regimen and will calculate how many 100 mg, 500 mg and 1000 mg vials are required for each cycle and for the full planned course.

You should not attempt to choose cytarabine doses, alter vial strengths or modify your schedule on your own. If you experience new or worsening symptoms such as high fever, uncontrolled bleeding, sudden confusion, difficulty walking, severe abdominal pain, chest pain or shortness of breath during cytarabine-based treatment, seek urgent medical attention rather than adjusting or stopping therapy yourself. Generic Meds Mart exists to help ensure that the Cytalon cytarabine your specialists have selected is available in the right strengths at the right time, while the complex medical management of your cancer remains in the hands of your haematology team.

FAQ about Cytalon (Cytarabine)

Q1: What types of cancer is Cytalon used to treat?

Cytalon contains cytarabine, an antimetabolite chemotherapy used mainly in the treatment of acute leukaemias and some related blood cancers. Depending on the protocol, cytarabine can be part of induction, consolidation or intensification regimens for acute myeloid leukaemia and other leukaemia subtypes, always under specialist supervision.

Q2: How is Cytalon different from oral chemotherapy?

Cytalon cytarabine is supplied as vials of lyophilised powder that must be reconstituted and given by injection or infusion, not taken by mouth. This allows precise control over dose and route, including intravenous, subcutaneous and, in selected cases, intrathecal administration. Because it is a potent cytotoxic medicine, Cytalon is prepared and administered only in hospitals or specialist centres, unlike some oral chemotherapy tablets that patients may take at home according to instructions.

Q3: Will I need to stay in hospital while receiving Cytalon?

Whether treatment with Cytalon cytarabine requires inpatient admission or can be given in a day-case setting depends on the specific regimen, your overall health, blood counts and the intensity of monitoring required. Some cytarabine schedules are delivered during hospital stays, while others may be administered in day-care units with regular visits. Your haematology team will explain the planned setting for each phase of your cytarabine-based therapy.

Q4: Can Cytalon be used again if my leukaemia relapses?

In some situations cytarabine can be used in more than one phase of therapy, for example in both initial induction and later relapse regimens, but this depends on your previous exposure, cumulative dose, response and side-effect profile. Your haematologist will consider prior treatments, remission duration and current disease features before deciding whether another cytarabine-containing regimen, including Cytalon, is appropriate in the relapse setting.

Q5: What can I do to reduce infection risks while on Cytalon?

Because cytarabine lowers white blood cell counts, infection prevention is very important during Cytalon treatment. Your team may recommend measures such as careful hand hygiene, avoiding crowds and people with obvious infections, following any neutropenic diet advice given locally, and promptly reporting fevers or signs of infection. In some regimens, prophylactic antibiotics, antivirals or antifungals may be used. Your haematology unit will provide specific written guidance tailored to your situation.

Celplat 50 mg/50 mL Cisplatin Injection (1 pack / 1 vial)

At a Glance

Generic Name: Cisplatin

Brand Name: Celplat

Strength & Pack Size: 50 mg/50 mL (1 mg/mL) solution; 1 pack / 1 vial

Dosage Form & Route: Sterile solution for IV infusion after dilution (hospital/clinic use)

Therapeutic Class: Platinum-based antineoplastic (alkylating-like chemotherapy)

Primary Indication: Testicular, ovarian, and bladder cancers where cisplatin-based regimens are appropriate

Typical Use in Therapy: Given in cycles, often as part of combination chemotherapy under oncology supervision

Usual Adult Dose: Individualised by protocol and specialist; dosing depends on body surface area, kidney function and regimen

Prescription Status: Prescription-only, administered by healthcare professionals

Storage: Store as directed on the vial/carton; protect from light and keep out of reach of children

Product Description

Celplat 50 mg/50 mL contains cisplatin, a platinum-based anticancer medicine used in multiple solid tumours. This presentation provides 1 pack / 1 vial containing 50 mg of cisplatin in 50 mL solution, designed for dilution and intravenous infusion in a clinic or hospital setting. Cisplatin is not a home-use medicine and should only be used when there is a confirmed diagnosis and a treatment plan created by an oncology team.

Cisplatin is widely used because it can be an effective backbone drug in combination regimens. Depending on local guidelines and your individual case, cisplatin may be part of protocols for testicular cancer, ovarian cancer, and bladder cancer, and it may also be used in certain settings for cervical cancer, head and neck cancers, or lung cancer when a cisplatin-based approach is clinically indicated. The exact regimen, combination partners and cycle timing are defined by your treating oncologist, not by self-selection.

Generic Meds Mart supplies Celplat cisplatin injection in original manufacturer packaging sourced through licensed channels. The carton and vial typically show the brand name, active ingredient, strength/concentration, batch number and expiry date to support verification by hospital pharmacies and infusion centres. Orders are shipped in discreet outer packaging to protect privacy, and delivery options may include tracking where regulations allow. Generic Meds Mart supports access and logistics only; all decisions about cisplatin use, cisplatin dosage and monitoring remain with your treating specialists.

Key Uses

Celplat cisplatin injection is commonly used in testicular cancer combination chemotherapy, including protocols where cisplatin is a key component under specialist supervision. Treatment intent and schedule are determined by your oncology team based on tumour type, stage and response assessment.

Celplat may also be used in ovarian cancer regimens, including combination treatment plans where platinum therapy is appropriate according to local standards and prior therapy history. Your specialist will consider previous exposure to platinum drugs, overall treatment goals and expected tolerability before selecting a cisplatin-based regimen.

In bladder cancer, cisplatin-based chemotherapy is often considered for eligible patients, including in neoadjuvant settings or in advanced disease, depending on kidney function, performance status and other clinical factors. Because cisplatin can be intensive and requires close monitoring, eligibility is individualised and alternatives may be considered when standard cisplatin dosing is not suitable. In some protocols, cisplatin is also used with radiotherapy in cervical cancer or head and neck cancers, but such use must follow specialist guidance and local regulations.

How Cisplatin Works in Chemotherapy

Cisplatin works mainly by forming platinum–DNA adducts inside cells. After administration, cisplatin becomes activated and binds to DNA, creating cross-links within and between DNA strands. These cross-links disrupt DNA replication and transcription, triggering cell-cycle arrest and apoptosis, particularly in rapidly dividing cancer cells.

Because cisplatin affects fundamental DNA processes, it can be active across multiple tumour types, especially when combined with other anticancer agents that damage cells through complementary mechanisms. The same DNA-damaging activity can also affect healthy tissues, which is why oncology teams use supportive care, careful dosing and monitoring to reduce risks while maintaining treatment effectiveness.

Dosage & Administration

Celplat cisplatin injection is administered only by healthcare professionals. The vial is typically diluted into an appropriate infusion fluid and given intravenously over a time period specified by the protocol. Dosing is individualised and may be calculated by body surface area, kidney function, blood counts and the specific combination regimen being used. Treatment is usually delivered in cycles with rest periods between cycles, and dose adjustments may be required based on side effects and laboratory results.

Hydration and electrolyte management are important parts of cisplatin administration because kidney toxicity is a key risk. Many protocols include pre- and post-infusion IV fluids and may include magnesium or potassium supplementation. Antiemetic medicines are usually given to reduce nausea and vomiting. Never self-adjust a cisplatin regimen and do not attempt to use this medicine outside a clinic setting. If an infusion is delayed or a cycle is missed, your oncology team will decide how to adjust the schedule safely.

Precautions

Cisplatin can cause significant kidney toxicity, so kidney function tests are routinely monitored before and during therapy. Patients with reduced kidney function may not be eligible for standard cisplatin dosing, and alternatives may be considered by the oncologist. Cisplatin can also cause severe nausea and vomiting without appropriate prevention, so antiemetic plans are essential.

Blood counts may drop during therapy, increasing the risk of infections and bleeding. Report fever, chills, sore throat, easy bruising or unusual bleeding promptly. Cisplatin may cause peripheral neuropathy and hearing-related effects such as tinnitus or hearing loss, which can be cumulative. Tell your team about numbness, tingling, balance changes, ringing in the ears or any hearing changes as early reporting helps clinicians assess risk and adjust treatment when needed.

Electrolyte disturbances such as low magnesium or potassium can occur and may require replacement. Infusion-site reactions and tissue injury can occur if cisplatin leaks outside the vein, so infusions should be administered with appropriate IV access and close observation. Cisplatin is harmful in pregnancy and can affect fertility; discuss contraception and fertility planning with your specialist before treatment. Always share a complete list of medicines and supplements with your oncology team, especially drugs that may affect kidneys or hearing, so overlapping toxicities and interactions can be managed.

Cisplatin Side Effects

Common side effects

Common cisplatin side effects include nausea and vomiting, loss of appetite, fatigue, taste changes and temporary changes in blood counts. Some patients experience constipation or diarrhoea, mouth soreness and transient changes in kidney tests monitored by the clinic. Tingling in the hands or feet, mild numbness or ringing in the ears can occur, especially as cumulative doses increase. Injection-site discomfort may occur during infusion and should be reported to staff.

Serious side effects

Serious side effects require urgent medical attention and may include significant reduction in kidney function, decreased urine output, swelling or severe electrolyte abnormalities. Severe infections due to low white blood cells, uncontrolled bleeding due to low platelets or severe anaemia can occur and may require hospital care. Hearing loss, persistent or worsening neuropathy, severe allergic or infusion reactions and severe uncontrolled vomiting or dehydration are also serious concerns. If you develop high fever, severe shortness of breath, chest pain, confusion, fainting, heavy bleeding, black stools, rapidly worsening weakness or markedly reduced urination, seek urgent care and tell clinicians you are receiving cisplatin.

Storage

Celplat cisplatin vials should be stored according to the instructions printed on the vial and carton, protected from light and kept in the original packaging until use. Storage, dilution and handling are typically managed by hospital pharmacy services following cytotoxic safety procedures. Do not use the product after the expiry date, and ensure unused medicine or materials are disposed of as hazardous pharmaceutical waste according to local regulations. Patients are not usually expected to store cisplatin at home; if transport is required, follow the clinic’s written instructions.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for oncology medicines such as Celplat cisplatin injection. We supply products in original packaging from licensed sources with batch and expiry information visible for verification by pharmacies and clinics. Pricing is shown in USD, and orders can be placed through secure checkout.

Where regulations allow, shipments are sent in discreet outer packaging with tracking options to help coordinate delivery with chemotherapy schedules and appointments. Generic Meds Mart does not provide individual medical advice or determine chemotherapy regimens. Decisions about whether cisplatin is appropriate, the correct dose and how to manage side effects must be made by your treating oncology team.

Order Now

Before you buy Celplat 50 mg/50 mL cisplatin injection online from Generic Meds Mart, make sure your oncologist has confirmed that a cisplatin-based regimen is appropriate and has specified the required dose, cycle schedule and monitoring plan. Your clinic will also confirm kidney function, blood counts, hydration strategy and supportive medicines such as antiemetics before each cycle.

Once your treatment plan is confirmed, select Celplat 50 mg/50 mL (1 pack / 1 vial), choose the quantity needed for the planned cycles and complete secure checkout in USD. Orders are supplied in original packaging with discreet delivery options where permitted, but do not attempt to administer cisplatin yourself or modify the schedule without specialist guidance. For questions about cisplatin dosage, cisplatin side effects or missed cycles, contact your treating oncology team.

FAQ about Celplat (Cisplatin)

Q1: What is Celplat 50 mg/50 mL used for?

Celplat contains cisplatin, a platinum-based chemotherapy medicine used in several solid tumours. It is commonly included in regimens for testicular, ovarian and bladder cancers when prescribed by an oncologist.

Q2: Is Celplat given as a quick injection or an infusion?

Celplat is typically diluted and given by intravenous infusion under clinical supervision. The infusion time and dilution method depend on the protocol used by your oncology team.

Q3: Why are hydration and blood tests important with cisplatin?

Hydration helps reduce kidney toxicity risk, and blood tests monitor kidney function, electrolytes and blood counts. These checks help clinicians adjust treatment and manage side effects safely.

Q4: What should I do if I feel tingling or notice hearing changes?

Tell your oncology team promptly if you develop numbness, tingling, ringing in the ears or hearing changes. These symptoms may indicate cisplatin-related nerve or hearing effects that require assessment.

Q5: Can I take other medicines during cisplatin treatment?

Many patients take supportive medicines during treatment, but interactions and overlapping toxicities are important. Provide your oncologist and pharmacist with a full list of medicines and supplements so they can advise what is safe with your regimen.

Bucelon 2 mg Busulfan Tablets (1 pack / 25 tabs)

At a Glance

Generic Name: Busulfan

Brand Name: Bucelon

Strength & Pack Size: 2 mg per tablet; 1 pack / 25 tablets

Dosage Form & Route: Oral tablet, swallowed whole with water

Therapeutic Class: Alkylating antineoplastic (chemotherapy)

Primary Indication: Conditioning before hematopoietic stem cell transplantation (HSCT) in selected protocols, and specialist-directed use in certain hematologic malignancies

Usual Adult Dose: Dose and schedule are highly protocol-specific and must be defined by your transplant or hematology–oncology specialist

Prescription Status: Prescription-only medicine

Storage: Store as directed on the carton; protect from moisture and keep out of reach of children

Product Description

Bucelon 2 mg contains busulfan, an alkylating chemotherapy medicine used in carefully planned treatment protocols under specialist supervision. Oral busulfan tablets are most commonly associated with conditioning regimens before hematopoietic stem cell transplantation (HSCT), where the goal is to prepare the bone marrow for transplantation by suppressing existing marrow function as part of a broader, physician-defined plan. Because busulfan has a narrow therapeutic window and clinically important risks, Bucelon 2 mg is not a routine outpatient medicine and should only be used when your specialist team has confirmed the indication, protocol, monitoring plan, and supportive care measures.

In transplant and hematology settings, busulfan is used as one component of multi-drug conditioning strategies. Depending on the protocol and local guidance, busulfan may be combined or sequenced with other agents to achieve adequate marrow suppression while balancing safety risks such as infection, bleeding, and organ toxicity. Treatment selection is individualized, and your team will consider diagnosis, transplant intent, prior therapies, liver function, infection risk, and concomitant medicines before choosing a busulfan-containing regimen. Bucelon 2 mg tablets should never be started, stopped, or adjusted without direct medical guidance, and decisions should not be made solely based on busulfan price or availability.

Generic Meds Mart supplies Bucelon 2 mg busulfan tablets in original packaging sourced through licensed channels. Packs typically display the brand name, strength, generic name, batch number, and expiry date to support verification by clinics and pharmacies. Orders are shipped in discreet outer packaging to support privacy, and delivery options may be available internationally where regulations allow. Our role is limited to access and logistics; your treating team remains responsible for all clinical decisions, including whether busulfan is appropriate, how it fits your conditioning plan, and how monitoring is performed.

Key Uses

Bucelon 2 mg busulfan tablets are primarily used as part of conditioning regimens before HSCT, where busulfan contributes to bone marrow suppression and preparation for transplantation. Conditioning is a complex process managed by transplant specialists and typically includes multiple medicines, supportive care, and strict monitoring. The exact intent of therapy and the conditioning approach depend on the transplant type, disease status, and protocol used by your center.

In some specialist-directed settings, busulfan has also been used in selected hematologic malignancies when appropriate and when alternative options are unsuitable, based on clinical judgment and local guidelines. These decisions are made by hematology–oncology teams who can evaluate risks, benefits, and monitoring requirements. If you plan to order busulfan online, confirm the exact strength and pack size with your clinic and ensure you have a clear plan for monitoring blood counts and organ function.

How Busulfan Works in Chemotherapy

Busulfan is an alkylating agent, meaning it can form chemical bonds with DNA in cells. By creating DNA cross-links, busulfan interferes with DNA replication and cell division. Cells that divide rapidly, including bone marrow precursor cells, are particularly affected. This property explains why busulfan can be used in conditioning regimens, where controlled suppression of bone marrow activity is required as part of preparation for stem cell transplantation.

Because busulfan affects bone marrow function, it can lead to profound reductions in white blood cells, red blood cells, and platelets. This is not an incidental side effect but a central pharmacologic effect that must be carefully planned and supported. In many protocols, specialists use structured monitoring and supportive care measures to reduce complications such as severe infection or bleeding. The intended benefit and the safety risks depend on the overall regimen, timing, and patient-specific factors, which is why busulfan must be used only within specialist-led protocols.

Dosage & Administration

Bucelon 2 mg tablets must be taken exactly as prescribed by your transplant or hematology–oncology specialist. Busulfan dosage is highly protocol-specific, and dosing schedules can vary significantly depending on the conditioning regimen and institutional standards. Never self-adjust the dose, never change the timing, and never substitute advice from your specialist team with self-directed changes, even if you feel well or experience side effects.

Tablets are usually swallowed whole with water. Your specialist team may provide guidance on timing in relation to food and other medicines, and they may also prescribe supportive medicines to help manage nausea, reduce seizure risk in certain protocols, and protect against infection. Drug interactions can be clinically significant, so provide your team with a complete list of prescription medicines, over-the-counter products, and supplements. If a dose is missed, follow your clinic’s written instructions and contact your prescribing team for guidance rather than attempting to compensate by taking extra tablets.

Precautions

Busulfan can cause severe myelosuppression, which increases the risk of serious infections and bleeding. Your care team will typically monitor blood counts closely and may adjust supportive care based on results. Fever, chills, sore throat, new cough, unusual bruising, bleeding, severe fatigue, or shortness of breath require urgent medical assessment, especially during conditioning.

Liver toxicity is a key concern with busulfan, including a serious complication known as hepatic veno-occlusive disease (also called sinusoidal obstruction syndrome) in some conditioning contexts. Your team will assess liver function and other risk factors and may use preventive measures depending on protocol. Busulfan can also affect fertility and may cause harm to a developing pregnancy; effective contraception and fertility planning should be discussed with your specialist before treatment. Because busulfan is cytotoxic, it should be handled and stored carefully as instructed, and it should never be shared with anyone else.

Busulfan Side Effects

Common side effects

Common busulfan side effects may include nausea, vomiting, reduced appetite, mouth or throat irritation, diarrhea or constipation, fatigue, headache, and temporary changes in liver enzymes on blood tests. The most expected and clinically important effect is reduced blood counts, which can manifest as increased infection risk, anemia-related tiredness, or easy bruising. Many effects are managed with protocol-based supportive care, but you should report persistent or worsening symptoms promptly rather than changing doses independently.

Serious side effects

Serious side effects require urgent medical attention and may include high fever or signs of severe infection, uncontrolled bleeding, severe shortness of breath, chest pain, confusion, or severe weakness. Serious liver injury and hepatic veno-occlusive disease can present with right-sided abdominal pain, rapid weight gain, swelling, or jaundice and must be assessed immediately. Seizures can occur in certain settings, which is why specialists may prescribe preventive medicines in some protocols. Rare but important long-term risks can include lung complications and secondary malignancies, and these risks are evaluated and monitored by specialist teams as part of transplant care.

Storage

Store Bucelon 2 mg busulfan tablets as directed on the product carton and pharmacy label, protected from moisture and excessive heat, and keep out of reach of children. Keep tablets in their original packaging to avoid mix-ups and to preserve batch and expiry information for verification. Do not use the medicine after the expiry date. Because busulfan is used in specialist protocols, storage and handling may be coordinated by a clinic or pharmacy; follow any transport or storage instructions provided by your treatment center.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialist medicines such as Bucelon 2 mg busulfan tablets. We source through licensed channels and supply products in original packaging with clear batch and expiry information to support verification by clinics and pharmacies. Pricing is displayed in USD, checkout is secure, and orders are shipped in discreet outer packaging to support privacy.

Where regulations allow, international delivery and tracking options can help patients and clinics coordinate treatment timelines. Generic Meds Mart does not provide medical decisions or replace your treating specialist. All decisions about whether busulfan is appropriate, how it is dosed, and how side effects are monitored must be made by qualified healthcare professionals following approved protocols.

Order Now

Before you buy Bucelon 2 mg online from Generic Meds Mart, you should have a confirmed plan from your transplant or hematology–oncology team that includes busulfan as part of conditioning or another specialist-directed regimen. Ensure your team has specified the correct strength and pack size and has provided written guidance on monitoring, supportive medicines, and what symptoms require urgent contact. Once your plan is confirmed, select Bucelon 2 mg (1 pack / 25 tabs), add it to your cart, and complete secure checkout in USD.

Do not start busulfan on your own, do not change busulfan dosage without instruction, and do not ignore warning symptoms. If you develop fever, unusual bleeding, severe shortness of breath, severe abdominal pain, jaundice, or rapidly worsening symptoms, seek urgent medical care and inform clinicians that you are taking busulfan.

FAQ about Bucelon (Busulfan)

Q1: What is Bucelon 2 mg used for?

Bucelon 2 mg contains busulfan, an alkylating chemotherapy medicine most commonly used as part of conditioning regimens before hematopoietic stem cell transplantation under specialist supervision. Your team decides if it is appropriate based on protocol and diagnosis.

Q2: Is Bucelon a routine at-home chemotherapy tablet?

No. Although it is an oral tablet, busulfan is typically used within strict specialist-led protocols with close monitoring because of serious risks such as severe myelosuppression and organ toxicity. Follow your transplant or hematology team’s instructions exactly.

Q3: How is busulfan dosing decided?

Busulfan dosing is protocol-specific and is determined by your specialist team based on the conditioning regimen, clinical factors, and monitoring requirements. You should never change busulfan dosage or timing on your own.

Q4: What interactions or precautions should I mention to my doctor?

Tell your team about all medicines and supplements you take, as interactions can be clinically important. Also discuss liver history, infection history, bleeding risk, fertility plans, and pregnancy prevention, because these factors can affect safety and monitoring.

Q5: What symptoms should prompt urgent medical attention?

Seek urgent care for fever, chills, new cough, uncontrolled bleeding, severe shortness of breath, chest pain, confusion, severe weakness, or signs of liver problems such as jaundice, swelling, rapid weight gain, or severe abdominal pain.

Bleocel 15 IU Bleomycin Injection (1 vial)

At a Glance

Generic Name: Bleomycin (as bleomycin sulfate)

Brand Name: Bleocel

Strength & Pack Size: 15 IU (15,000 IU) bleomycin per vial; 1 vial

Dosage Form & Route: Lyophilised powder for solution for injection/infusion; administered by healthcare professionals (route per protocol)

Therapeutic Class: Antineoplastic antibiotic (cytotoxic chemotherapy)

Primary Indication: Hodgkin lymphoma and testicular germ cell cancer within combination chemotherapy regimens

Usual Adult Dose: Regimen-based dosing defined by an oncologist; cumulative exposure and monitoring requirements apply

Prescription Status: Prescription-only / hospital-use medicine

Storage: Store refrigerated as directed on the pack; protect from light; do not use after expiry

Product Description

Bleocel 15 IU Injection contains bleomycin, an antineoplastic antibiotic used in oncology as part of combination chemotherapy regimens. Bleomycin is supplied as a lyophilised powder that must be reconstituted by trained professionals and administered according to protocol in a hospital or specialist treatment setting. Bleocel 15 IU is commonly requested for established regimens in Hodgkin lymphoma and testicular germ cell cancer, where bleomycin may be included based on guideline recommendations, patient factors and specialist judgement.

Each Bleocel pack provides 1 vial containing 15 IU (15,000 IU) of bleomycin, supporting accurate ordering for a prescribed treatment plan. Because cancer regimens are planned in cycles and may require dose modifications, it is important to confirm the required number of vials with the treating oncology team before purchasing. When reviewing bleomycin price or availability online, always compare the same strength and pack size (Bleocel 15 IU, 1 vial) so budgeting and supply planning remain consistent with the clinic’s protocol.

Generic Meds Mart supplies Bleocel 15 IU bleomycin injection in original packaging from licensed distribution channels. Product labelling includes strength, batch details and expiry information so hospital pharmacies and oncology teams can verify identity during routine safety checks. Orders are shipped in discreet outer packaging to protect privacy, and international delivery is available where regulations allow. Our role is limited to access and logistics; all clinical decisions about whether bleomycin is appropriate, how it is combined with other medicines and how side effects are monitored remain with the treating specialists.

Key Uses

Bleocel 15 IU bleomycin injection is used primarily within combination chemotherapy regimens for Hodgkin lymphoma and testicular germ cell cancer. In Hodgkin lymphoma, bleomycin-containing combinations may be selected to treat newly diagnosed disease or selected relapsed settings depending on local protocols, risk profile and treatment goals defined by the oncology team.

In testicular germ cell cancer, bleomycin may be included in specialist regimens aimed at achieving cure or long-term disease control, with careful attention to monitoring and cumulative exposure. The exact place of bleomycin in therapy depends on tumour subtype, stage, overall fitness and other clinical factors, and the final regimen is determined by the treating oncologist in line with local standards of care.

In some settings, bleomycin may also be used for selected other malignancies where bleomycin-containing protocols are locally approved and clinically appropriate. In addition, bleomycin can be used in certain procedural oncology pathways such as chemical pleurodesis for malignant pleural effusion, when performed by specialists in controlled settings. Any such use must follow institutional protocols and local regulations, and it should never be substituted or started without specialist oversight.

How Bleomycin Works in Chemotherapy

Bleomycin works by binding to DNA and generating free-radical mediated damage that leads to single- and double-strand breaks. This disrupts DNA synthesis and repair, resulting in cell-cycle arrest and apoptosis, particularly in rapidly dividing malignant cells. In combination chemotherapy, bleomycin contributes a distinct mechanism that complements other agents targeting different cellular pathways.

A clinically important feature of bleomycin is its tissue-specific toxicity profile. Because pulmonary toxicity is a known risk, oncology teams apply regimen-specific dose limits and monitoring strategies to reduce harm while preserving treatment effectiveness. Patients are monitored for respiratory symptoms and overall tolerance throughout therapy, and treatment plans may be adjusted if the risk of lung injury becomes significant.

Dosage & Administration

Bleocel 15 IU bleomycin injection must be dosed and administered only by trained healthcare professionals. The dose and schedule are regimen-based and depend on the protocol selected by the oncologist, patient characteristics, kidney function and cumulative exposure considerations. Bleomycin is prepared and administered in clinical settings where patients can be observed and supportive care can be provided if needed.

Reconstitution, dilution and handling are managed by hospital pharmacy and nursing staff using cytotoxic safety procedures. Patients should never self-administer bleomycin, attempt to prepare vials at home or self-adjust the schedule. If a dose is delayed or missed, only the treating team can decide how to proceed based on protocol rules, monitoring results and clinical status.

Precautions

Bleomycin therapy requires careful monitoring because of the risk of pulmonary toxicity. Patients should report new or worsening cough, shortness of breath, chest discomfort or unexplained fever promptly, especially during active treatment. The oncology team may perform baseline and follow-up assessments of lung function depending on the regimen and risk profile, and bleomycin may be reduced or discontinued if lung injury is suspected.

Bleomycin can also cause hypersensitivity reactions, and early doses are administered in settings equipped to manage acute reactions. Kidney function is clinically relevant because reduced clearance can increase exposure and toxicity risk, so renal assessment and ongoing review are important. Patients should provide a complete list of medicines and supplements, as the overall chemotherapy regimen and supportive medicines can influence safety and monitoring needs.

Pregnancy and breastfeeding precautions apply to cytotoxic chemotherapy. Effective contraception is typically recommended during treatment and for a period afterwards as advised by the specialist. Patients should not make independent decisions about pausing or restarting treatment, and any changes to therapy must be guided by the treating oncology team.

Bleomycin Side Effects

Common side effects

Common side effects may include fever or flu-like symptoms after dosing, fatigue, nausea, reduced appetite and general weakness, often influenced by the full combination regimen. Skin and mucosal reactions can occur, including rash, itching, hyperpigmentation, nail changes or mouth irritation. Some patients experience soreness at the injection site or discomfort related to venous access devices used for infusion. These effects are monitored as part of routine oncology care, and supportive medicines may be used to improve tolerability.

Serious side effects

Serious adverse effects require urgent medical attention. New or worsening respiratory symptoms such as persistent cough, shortness of breath or chest tightness can indicate possible lung toxicity and must be assessed promptly. Severe allergic reactions, rapidly worsening fever with signs of infection, or severe skin reactions with blistering or widespread painful rash also require urgent evaluation. Because chemotherapy can affect overall resilience and immune function depending on the regimen, patients should seek immediate care for alarming symptoms and inform clinicians that bleomycin is part of the treatment plan.

Storage

Bleocel 15 IU should be stored as stated on the manufacturer label and is commonly kept refrigerated in controlled pharmacy storage to protect stability and maintain traceability. Hospital pharmacies typically manage storage, reconstitution, dilution and cytotoxic waste disposal according to hazardous-drug procedures. Patients are rarely expected to store bleomycin vials at home; if temporary transport or storage is required, it must follow written instructions from the treating facility.

Why Buy from Generic Meds Mart

Generic Meds Mart helps patients and clinics access essential oncology medicines such as Bleocel 15 IU bleomycin injection through structured sourcing and reliable logistics. We supply Bleocel in original packaging with clear batch and expiry details so pharmacies and oncology teams can verify product identity as part of standard safety workflows. Orders are processed in USD, supporting treatment planning across cycles without ambiguity about the pack size.

Shipments are packed in discreet outer cartons to protect privacy, and international delivery with tracking is available where regulations allow. Generic Meds Mart does not replace the treating oncologist; decisions about whether bleomycin is appropriate, how it is administered and how side effects are managed must remain with qualified healthcare professionals.

Order Now

Before ordering Bleocel 15 IU from Generic Meds Mart, you should have a confirmed diagnosis and a regimen recommendation from your oncology team that includes bleomycin at the appropriate dose and schedule. The clinic will determine how many vials are required based on the number of cycles, patient-specific dosing and potential dose adjustments guided by monitoring results.

Once a plan is in place, select Bleocel 15 IU Injection (1 vial), add it to your cart and complete secure checkout in USD. Your order is shipped in discreet packaging with international delivery where allowed. Do not start, stop or modify bleomycin therapy independently; any questions about dosing, timing or bleomycin side effects must be directed to your treating oncology team.

FAQ about Bleocel (Bleomycin)

Q1: What is Bleocel 15 IU used for?

Bleocel 15 IU contains bleomycin, which is used mainly as part of combination chemotherapy regimens for Hodgkin lymphoma and testicular germ cell cancer. The decision to include bleomycin depends on local protocols and your oncologist’s assessment of benefits and risks, including pulmonary considerations.

Q2: Is Bleocel taken by mouth or given by injection?

Bleocel is supplied as a vial of lyophilised powder for solution for injection/infusion. It is administered by trained healthcare professionals in clinical settings and is not suitable for self-administration at home.

Q3: How often is bleomycin given?

Bleomycin schedules are regimen-based and vary between protocols. Treatment is usually delivered in cycles with monitoring between doses, and only the treating oncology team can define the exact schedule or make adjustments.

Q4: What side effects should I watch for with bleomycin?

Your team will advise what to expect from the full regimen, but respiratory symptoms such as new cough or shortness of breath should be treated as urgent. Fever, severe rash or any rapidly worsening symptom should also be reported immediately, especially during active chemotherapy.

Q5: Do I need to store Bleocel at home?

Most patients do not store bleomycin at home because preparation and handling are managed by hospital pharmacies under cytotoxic safety procedures. If you are instructed to transport or temporarily store a vial, follow the facility’s written instructions and keep the vial in its original packaging.

Alkacel 50 mg/1 mL Melphalan Injection Ampoule

At a Glance

Generic Name: Melphalan

Brand Name: Alkacel

Strength & Pack Size: 50 mg/1 mL single-use melphalan injection ampoule

Dosage Form & Route: Cytotoxic concentrate for IV infusion after dilution, prepared in hospital

Therapeutic Class: Alkylating agent chemotherapy

Primary Indications: Multiple myeloma and selected conditioning regimens for haematopoietic stem cell transplantation, as per local label

Typical Use in Therapy: Used in specialist oncology and haematology protocols alongside other chemotherapies and supportive medicines

Prescription Status: Prescription-only cytotoxic medicine for use in hospitals or accredited infusion centres

Storage: Store in a refrigerator at 2–8 °C in the original carton; protect from light and follow cytotoxic handling procedures

Product Description

Alkacel 50 mg/1 mL is a melphalan-based injectable chemotherapy supplied as a single-use ampoule intended for dilution and intravenous infusion in controlled hospital settings. Melphalan is an alkylating agent that has played a central role in multiple myeloma treatment and in certain high-dose conditioning regimens prior to haematopoietic stem cell transplantation. Each Alkacel ampoule contains 50 mg melphalan in 1 mL, which must be diluted according to the product information and institutional protocols before being given to the patient.

Because melphalan is highly active against dividing cells and unstable in solution, Alkacel must only be prepared by trained pharmacists or chemotherapy nurses using aseptic technique in a designated preparation area. The diluted infusion is administered via a central line or peripheral vein over a defined period, with careful monitoring of vital signs and laboratory parameters. Alkacel injection is never self-administered and is not suitable for home use.

Generic Meds Mart supplies Alkacel 50 mg/1 mL ampoules in original manufacturer cartons obtained from licensed oncology distributors. Each carton and ampoule is labelled with the brand name, generic name, strength, batch number, expiry date and storage conditions so that hospital pharmacy teams can verify every unit before it enters chemotherapy preparation workflows. Parcels are shipped in plain outer packaging without visible references to myeloma, transplantation or chemotherapy, supporting patient privacy while maintaining full traceability of oncologic medicines. Our role is limited to medicine access and logistics; all treatment decisions remain with your specialist team.

Key Uses

Alkacel melphalan injection is most commonly used in multiple myeloma. At conventional doses, melphalan may form part of systemic treatment regimens, often in combination with other chemotherapies, immunomodulatory agents or corticosteroids. At high doses, melphalan is frequently used as a conditioning agent before autologous stem cell transplantation in eligible patients, with the aim of achieving deeper remission in relapsed or newly diagnosed myeloma.

In some centres and according to local approvals, melphalan may also be used in selected other haematologic malignancies or conditioning protocols. The exact indication, dose and schedule for Alkacel are always defined by experienced haematologists or oncologists who are familiar with melphalan-containing regimens and with the supportive care required during treatment.

How Melphalan Works in Chemotherapy

Melphalan, the active ingredient in Alkacel, is a bifunctional alkylating agent related to nitrogen mustard. It acts by forming covalent bonds with DNA, leading to cross-linking of DNA strands and interference with replication and transcription. This damage is particularly harmful to rapidly dividing cells such as malignant plasma cells in multiple myeloma, which rely on continuous DNA synthesis to survive and proliferate.

By creating DNA cross-links and associated strand breaks, melphalan triggers cell-cycle arrest and programmed cell death in susceptible tumour cells. Normal tissues with high turnover, such as bone marrow and gastrointestinal mucosa, are also affected to some degree, which explains many of the treatment-limiting toxicities associated with melphalan. In the high-dose transplant setting, melphalan is used to deliver a powerful cytotoxic hit to residual myeloma cells, followed by infusion of stem cells to re-establish healthy blood formation.

Dosage & Administration

Dosing of Alkacel melphalan injection is highly individualised and must always follow an approved protocol under specialist supervision. Regimens may use body-surface-area–based dosing expressed in mg/m², fixed mg doses or high-dose schedules in the transplant setting. The same 50 mg/1 mL ampoule can therefore be used in very different ways depending on whether the goal is systemic disease control or intensive conditioning.

Alkacel ampoules are drawn up and diluted with the specified diluent by trained staff in a pharmacy clean room or chemotherapy preparation area. Because melphalan solutions are not stable for long, the prepared infusion is typically used promptly within the time limits given in the product information. Patients receive the infusion intravenously, usually over a set period, with regular monitoring of blood pressure, heart rate, temperature and other clinical parameters. Concomitant antiemetics, hydration and other supportive medicines are often used to help manage side effects. Patients should never attempt to prepare or administer melphalan themselves.

Precautions

Before starting Alkacel, your medical team will carefully review your overall health, cardiac and renal function, liver status, pulmonary history and previous exposure to chemotherapy and radiotherapy. Melphalan can cause profound bone marrow suppression, so baseline blood counts and frequent monitoring during and after treatment are essential. Existing infections must be addressed, and prophylactic antimicrobials may be recommended in high-risk regimens.

Melphalan has mutagenic and potentially carcinogenic properties, and prior or concomitant therapies may influence the long-term risk of therapy-related myeloid neoplasms. Fertility may be affected, particularly with high-dose melphalan, and fertility preservation options are often discussed before treatment where feasible. Effective contraception is usually required during and for a period after melphalan therapy; Alkacel is generally avoided during pregnancy and breastfeeding unless the potential benefit clearly outweighs the risks and this is documented by the treating team.

Melphalan Side Effects

Common side effects

Common melphalan side effects include bone marrow suppression with neutropenia, anaemia and thrombocytopenia, leading to increased susceptibility to infections, fatigue, shortness of breath and easy bruising or bleeding. Nausea, vomiting, diarrhoea, abdominal discomfort and mucositis or mouth sores may occur, especially at higher doses. Many patients experience hair thinning or hair loss, temporary changes in taste and appetite loss during treatment. Transient increases in liver enzymes or mild changes in kidney function may also be observed and are monitored through regular blood tests.

Serious side effects

Serious melphalan adverse effects require urgent medical attention and may necessitate dose reduction, treatment delay or discontinuation. These include severe infections or sepsis, marked thrombocytopenia with significant bleeding, prolonged or profound neutropenia, serious gastrointestinal toxicity, pulmonary complications and, rarely, severe hepatic or renal impairment. Over the longer term, there is a recognised risk of therapy-related myelodysplastic syndromes or acute leukaemias in some patients exposed to alkylating agents such as melphalan, particularly when combined with other intensive treatments. Any high fever, uncontrolled bleeding, chest pain, sudden shortness of breath, confusion, severe abdominal pain or other alarming symptom during or after Alkacel therapy should be reported immediately to your haematology team or emergency services.

Storage

Unopened Alkacel 50 mg/1 mL ampoules should be stored in a refrigerator at 2–8 °C in their original cartons, protected from light and moisture, and handled according to local cytotoxic medicine guidelines. Prepared melphalan infusions have limited stability and must be used or discarded within the time frame specified in the product information and institutional protocols. Patients are not expected to store or handle Alkacel ampoules or prepared infusions at home; all storage, preparation and disposal are managed by hospital or infusion centre staff using appropriate cytotoxic waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on helping patients and clinics access essential oncology medicines such as Alkacel melphalan injection in regions where local supply or cost can be challenging. We work only with licensed manufacturers and authorised distributors that follow recognised quality standards and maintain full batch and expiry traceability. By supplying Alkacel 50 mg/1 mL ampoules in sealed original cartons, we support hospital pharmacies in verifying that each unit matches the melphalan brand and strength specified in their treatment protocols.

All Alkacel orders placed through Generic Meds Mart are processed in USD via secure online checkout. Parcels are shipped in neutral outer packaging with no visible references to multiple myeloma, transplantation or chemotherapy. Where available, tracked shipping options help oncology teams plan treatment dates and transplant schedules around confirmed delivery windows, reducing the risk of delays caused by supply interruptions. Our role is to support timely and discreet access to melphalan; decisions about whether Alkacel is appropriate and how it should be used remain entirely with your specialists.

Order Now

Before you order Alkacel 50 mg/1 mL online from Generic Meds Mart, you should already have a confirmed diagnosis and a written treatment plan from your haematologist or oncologist that specifically includes melphalan, the intended dose and the number of cycles or conditioning schedule. Your treatment centre will calculate how many Alkacel ampoules are needed and will usually coordinate delivery so that pharmacy and chemotherapy units receive the medicine in advance of planned treatment dates.

You should never attempt to self-prescribe melphalan, modify the dose on your own or substitute between different melphalan products without direct guidance from your healthcare team. If you experience new or worsening symptoms such as high fever, uncontrolled bleeding, persistent vomiting, chest pain, sudden shortness of breath or marked weakness during or after melphalan-based therapy, seek urgent medical attention. Generic Meds Mart exists to support reliable, discreet supply of Alkacel melphalan injection, while the complex clinical management of your cancer remains with your specialist team.

FAQ about Alkacel (Melphalan)

Q1: What conditions is Alkacel used to treat?

Alkacel contains melphalan, an alkylating agent used mainly in multiple myeloma and certain high-dose conditioning regimens before haematopoietic stem cell transplantation. In some centres, melphalan may also be used in selected other haematologic indications according to local approvals and guidelines.

Q2: Is Alkacel given as a drip or an injection?

Alkacel 50 mg/1 mL is supplied as an injectable melphalan formulation that must be diluted and given intravenously in hospital. Depending on the protocol, it may be infused over a defined period through a central or peripheral line. It is not intended for intramuscular injection or self-administration at home.

Q3: Will I lose my hair with Alkacel?

Hair thinning or hair loss can occur with melphalan, particularly when it is used at higher doses or in combination with other chemotherapies. Not every patient loses all hair, and regrowth usually occurs after treatment finishes, although timing varies. Your oncology team can give you a more precise estimate based on your overall regimen.

Q4: How will my doctors monitor me during Alkacel treatment?

During Alkacel therapy you will have regular blood tests to monitor blood counts, kidney and liver function, as well as clinical assessments to check for infections, bleeding, gastrointestinal symptoms and other side effects. In the transplant setting, monitoring is particularly intensive, with daily reviews until blood counts recover and complications are under control.

Q5: Can Alkacel be substituted with oral melphalan tablets?

Oral melphalan and injectable melphalan have different dosing, absorption and stability characteristics. Substitution between Alkacel injection and oral melphalan tablets is not a simple milligram-for-milligram switch and must only be done by specialists using validated protocols. You should not change formulation or brand on your own; any adjustments must be made by your haematology team.

Alkacel Melphalan – 2 mg Tablets (1 pack / 25 tabs)

At a Glance

Generic Name: Melphalan

Brand Name: Alkacel

Strength & Pack Size: 2 mg tablets, 1 pack / 25 tabs

Dosage Form & Route: Oral tablets for swallowing with water

Therapeutic Class: Alkylating antineoplastic agent (nitrogen mustard derivative)

Primary Indications: Multiple myeloma and selected other haematologic or solid tumour protocols as per local label

Typical Use in Therapy: Part of induction, consolidation or palliative regimens, sometimes with steroids or other agents

Mode of Action: Cross-links DNA to inhibit replication and trigger cancer cell death

Key Benefits: Long-established backbone drug in multiple myeloma regimens with flexible oral dosing

Precautions: Myelosuppression, infection risk, nausea, fertility impact and potential long-term secondary malignancy risk

Storage: Store below 25 °C in original cytotoxic packaging, away from moisture and children

Product Description

Alkacel 2 mg contains melphalan, a classic alkylating agent used for decades in the treatment of multiple myeloma and certain other malignancies. This oral presentation provides 2 mg melphalan tablets in a 1 pack / 25 tabs format, allowing haematology–oncology teams to build precise daily or intermittent doses tailored to the treatment protocol and the individual patient’s condition. Alkacel is a cytotoxic medicine that must only be prescribed and supervised by specialists experienced in systemic chemotherapy.

In multiple myeloma, melphalan has historically been combined with drugs such as steroids and, in some settings, novel agents to achieve remission or disease control. While treatment paradigms have evolved to include proteasome inhibitors, IMiDs and monoclonal antibodies, melphalan remains relevant in certain oral combination regimens and in conditioning strategies, according to region and current guidelines. Alkacel 2 mg tablets provide a low-strength, tablet-based option that supports fine-tuning of melphalan dosage when oral therapy is chosen.

Generic Meds Mart offers Alkacel 2 mg melphalan tablets in original cytotoxic cartons or bottles from licensed manufacturers and distributors. Each pack is clearly labelled with the strength, tablet count, batch number and expiry date, enabling oncology pharmacies and clinics to verify authenticity and record lot details for pharmacovigilance. Outer shipping cartons are neutral and do not reference cancer, chemotherapy or melphalan, supporting privacy for patients and hospitals. Our role is restricted to access and logistics; all decisions about whether and how to use Alkacel belong to your treating team.

Key Uses

Within the framework of local approvals and current protocols, Alkacel 2 mg melphalan tablets are typically used for multiple myeloma in adults as part of systemic treatment plans. Melphalan may feature in oral combination regimens for patients who are not candidates for intensive transplant-based therapy, or it may be used in selected conditioning or cytoreductive schedules when an oral alkylating backbone is preferred.

Melphalan can also appear in regimens for certain other haematologic or solid tumours where older protocols remain in use or where local practice supports melphalan-based approaches. However, the most widely recognised indication for Alkacel 2 mg remains multiple myeloma, and any off-label use must be guided by a specialist who is fully familiar with the current evidence, alternatives and patient-specific risk factors.

How Melphalan Works in Chemotherapy

Melphalan, the active ingredient in Alkacel 2 mg tablets, is an alkylating agent derived from nitrogen mustard. Once in the body, melphalan forms highly reactive intermediates that bind to DNA, creating cross-links within and between DNA strands. These cross-links interfere with DNA replication and transcription, leading to faulty DNA repair and ultimately cell death, particularly in rapidly dividing cells such as malignant plasma cells in multiple myeloma.

As an S-phase–non-specific alkylating agent, melphalan exerts its effects throughout the cell cycle but is especially damaging when cells attempt to divide. This broad activity underpins its long-standing role in myeloma protocols. However, because normal rapidly dividing cells in the bone marrow, gastrointestinal tract and hair follicles may also be affected, careful dosing and monitoring are essential to balance efficacy and toxicity. Over time, exposure to alkylating agents such as melphalan can contribute to an increased risk of secondary malignancies, including therapy-related myelodysplastic syndromes and acute leukaemias, which is one reason specialist oversight is so important.

Dosage & Administration

Alkacel 2 mg melphalan tablets must never be used without a clear written regimen from a haematology–oncology specialist. Melphalan dosing is often based on body surface area, renal function, comorbidities, concomitant medicines, prior treatment history and overall treatment intent. Schedules can include continuous daily dosing, intermittent cycles, pulse dosing or combinations with steroids and other cytotoxic or targeted agents, depending on the protocol.

The 2 mg strength allows fine adjustments to the total daily dose; several tablets may be taken together to reach the prescribed amount. Tablets are usually swallowed whole with water and are not crushed or chewed due to the cytotoxic nature of the drug and the potential for altered absorption or increased exposure. Handling instructions, such as wearing gloves when splitting blister packs or avoiding direct contact with broken tablets, should follow local cytotoxic guidelines. If a dose is missed, patients must follow the specific instructions given by their treatment centre rather than taking extra tablets on their own initiative.

Precautions

Because melphalan is a potent myelosuppressive agent, close monitoring of full blood counts is essential during Alkacel therapy. Neutropenia, thrombocytopenia and anaemia are common and may require treatment delays, dose reductions, transfusions or growth factor support. Patients and caregivers should be aware of warning signs such as fever, sore throat, persistent cough, unexplained bruising, unusual bleeding or extreme fatigue, and should contact the treating team immediately if these occur.

Melphalan can also cause nausea, vomiting, diarrhoea, oral mucositis, hair thinning or loss and less commonly liver enzyme elevations or pulmonary toxicity. Renal impairment can alter drug handling, and dose adjustments may be needed in patients with reduced kidney function. Because melphalan is mutagenic and potentially carcinogenic, long-term use is associated with an increased risk of therapy-related myeloid malignancies. Alkacel is teratogenic and should not be used during pregnancy unless there are no alternatives and the potential benefit clearly outweighs the risk; effective contraception is recommended during treatment and for a period afterwards. Melphalan may affect fertility in all genders, so discussions about fertility preservation before starting therapy are important for many patients.

Melphalan Side Effects

Common side effects

Common melphalan side effects with Alkacel 2 mg tablets include bone marrow suppression with low white blood cells, red cells and platelets, increased susceptibility to infections, tiredness, weakness, nausea, vomiting, loss of appetite, mild diarrhoea or constipation, mouth soreness or ulcers, and hair thinning or partial hair loss. Some patients may notice mild skin changes or transient elevations in liver enzymes on blood tests.

These effects are often manageable with supportive measures such as antiemetics, mouth care routines, nutritional support, transfusions and growth-factor support where appropriate, combined with dose adjustments or schedule changes under specialist guidance. It is important not to stop melphalan tablets abruptly or change the dose without consulting the treating team, as they may be able to improve tolerability by modifying the regimen rather than discontinuing therapy entirely.

Serious side effects

Serious melphalan adverse effects require urgent medical attention. These can include severe or prolonged neutropenia with high fever or sepsis, severe thrombocytopenia with significant bleeding, profound anaemia causing chest pain or shortness of breath at rest, heavy or persistent gastrointestinal symptoms with dehydration, signs of liver injury such as jaundice and dark urine, new or worsening respiratory symptoms that could reflect pulmonary toxicity and, in the longer term, evidence of therapy-related myelodysplastic syndrome or acute leukaemia on blood or bone marrow tests.

If any of these serious warning signs appear during treatment with Alkacel 2 mg melphalan tablets, patients must seek emergency care and inform clinicians that they are receiving an alkylating agent. The haematology–oncology team may need to stop treatment, adjust doses, change regimens or introduce additional supportive therapies to manage complications.

Storage

Alkacel 2 mg melphalan tablets should be stored in their original cytotoxic packaging at a temperature specified in the product leaflet, generally below 25 °C, protected from moisture and direct heat. The pack should remain tightly closed when not in use, and tablets should only be removed immediately before dosing. As with all chemotherapy medicines, Alkacel must be kept out of the sight and reach of children and stored separately from everyday household medicines to prevent accidental ingestion. Unused or expired tablets and any materials contaminated with melphalan should be returned to a pharmacy or disposed of according to local hazardous or cytotoxic waste procedures, not in household rubbish.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to key oncology and haematology medicines such as Alkacel 2 mg melphalan tablets. We work only with licensed manufacturers and authorised distributors who comply with Good Manufacturing Practice standards and can provide verifiable batch and documentation trails. Each pack of Alkacel 2 mg we supply is original, sealed and labelled with strength, batch number and expiry date so hospital and clinic pharmacies can confirm authenticity.

Displaying Alkacel prices in USD helps patients and treatment centres plan multi-cycle therapy budgets more easily. Neutral outer packaging protects privacy, and trackable delivery options, where regulations allow, make it simpler to coordinate medicine arrival with clinic visits, blood tests and treatment dates. Our service does not replace your haematologist or oncologist and does not include personalised medical advice; we support access and logistics while treatment decisions remain strictly between you and your specialist team.

Order Now

Alkacel 2 mg melphalan tablets are powerful cytotoxic medicines and must never be started, stopped or adjusted without direct instruction from an experienced haematology–oncology team. Before you or your clinic buy Alkacel online from Generic Meds Mart, your diagnosis, treatment goals, alternative options and overall health status should be fully reviewed with your specialist, and a clear melphalan dosage and monitoring plan should be agreed in writing.

Once this plan is in place, your team can calculate how many Alkacel 2 mg tablets and how many packs of 1 pack / 25 tabs are needed for the next phase of therapy, taking into account any planned dose adjustments or treatment breaks. The required quantity can then be selected on Generic Meds Mart, added to the cart and checked out in USD. Medicines will be shipped in discreet packaging, and all subsequent questions about melphalan dosage, melphalan side effects or regimen changes must be directed to your treating specialists rather than managed independently.

FAQ about Alkacel (Melphalan)

Q1: What is Alkacel 2 mg used for?
Alkacel 2 mg contains melphalan, an alkylating chemotherapy agent mainly used in multiple myeloma and selected other haematology or oncology protocols. It is usually part of combination regimens rather than a single stand-alone treatment, and its use is defined by specialist guidelines.

Q2: Is Alkacel taken every day?
The schedule for Alkacel 2 mg melphalan tablets depends on the protocol your haematologist chooses. Some regimens involve short courses on specific days of a cycle, while others may use more continuous dosing. Only your treating team can explain the exact plan for your situation and whether daily or intermittent dosing is appropriate.

Q3: Can Alkacel tablets be cut or crushed?
Because melphalan is a cytotoxic drug, Alkacel tablets are usually swallowed whole to limit exposure to the powder and to keep absorption predictable. You should not cut, crush or chew Alkacel 2 mg tablets unless your treatment centre gives explicit written instructions and appropriate handling advice. If swallowing tablets is difficult, discuss alternative strategies with your specialist.

Q4: What monitoring will I need while on Alkacel?
Patients on Alkacel melphalan typically require regular full blood counts, kidney and liver function tests, and clinical assessment for signs of infection, bleeding, mucositis or other toxicities. In long-term use, your team may also watch for signs of therapy-related myeloid malignancies. All required tests and visit intervals will be outlined in your treatment plan.

Q5: What should I do if I miss a dose of Alkacel?
If you miss a dose of Alkacel 2 mg melphalan tablets, do not double the next dose unless your haematology team explicitly instructs you to do so. Contact your treatment centre as soon as possible and follow their advice; they may adjust your schedule or ask you to skip the missed dose depending on where you are in the cycle.